Cargando…

Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database

Multiple myeloma therapy has made remarkable progress with the advent of new drugs. We explored the treatment pattern and outcomes in Japanese patients with multiple myeloma using the Medical Data Vision database. Patients were categorized as per the initial diagnosis period (2003–2015 and 2016–2020...

Descripción completa

Detalles Bibliográficos
Autores principales: Handa, Hiroshi, Ishida, Tadao, Ozaki, Shuji, Mori, Asuka, Kato, Kenichi, Iida, Shinsuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079007/
https://www.ncbi.nlm.nih.gov/pubmed/37023056
http://dx.doi.org/10.1371/journal.pone.0283931
_version_ 1785020633950715904
author Handa, Hiroshi
Ishida, Tadao
Ozaki, Shuji
Mori, Asuka
Kato, Kenichi
Iida, Shinsuke
author_facet Handa, Hiroshi
Ishida, Tadao
Ozaki, Shuji
Mori, Asuka
Kato, Kenichi
Iida, Shinsuke
author_sort Handa, Hiroshi
collection PubMed
description Multiple myeloma therapy has made remarkable progress with the advent of new drugs. We explored the treatment pattern and outcomes in Japanese patients with multiple myeloma using the Medical Data Vision database. Patients were categorized as per the initial diagnosis period (2003–2015 and 2016–2020), considering the adoption of these new agents and then based on stem cell transplantation. Overall, 6438 patient data were extracted as eligible for data analysis, and the median age at the index diagnosis date was 72.0 years. Bortezomib/dexamethasone was the most common regimen for induction therapy in patients requiring stem cell transplantation from 2003–2015, and the use of bortezomib/lenalidomide/dexamethasone increased from 2016–2020. Lenalidomide/dexamethasone was the most commonly used post-transplant therapy. In the non-stem cell transplantation group, bortezomib/dexamethasone was mainly used for both periods, while lenalidomide/dexamethasone was primarily used from 2016–2020. There was a trend toward shorter first-line treatment duration and a shift to additional treatment patterns with new drugs at the following lines. The time to inpatient death period suggested an improvement between the two periods. Thus, this study revealed that recent diversification of treatment options is preferred and contributes to improved outcomes in the clinical practice of multiple myeloma in Japan.
format Online
Article
Text
id pubmed-10079007
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-100790072023-04-07 Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database Handa, Hiroshi Ishida, Tadao Ozaki, Shuji Mori, Asuka Kato, Kenichi Iida, Shinsuke PLoS One Research Article Multiple myeloma therapy has made remarkable progress with the advent of new drugs. We explored the treatment pattern and outcomes in Japanese patients with multiple myeloma using the Medical Data Vision database. Patients were categorized as per the initial diagnosis period (2003–2015 and 2016–2020), considering the adoption of these new agents and then based on stem cell transplantation. Overall, 6438 patient data were extracted as eligible for data analysis, and the median age at the index diagnosis date was 72.0 years. Bortezomib/dexamethasone was the most common regimen for induction therapy in patients requiring stem cell transplantation from 2003–2015, and the use of bortezomib/lenalidomide/dexamethasone increased from 2016–2020. Lenalidomide/dexamethasone was the most commonly used post-transplant therapy. In the non-stem cell transplantation group, bortezomib/dexamethasone was mainly used for both periods, while lenalidomide/dexamethasone was primarily used from 2016–2020. There was a trend toward shorter first-line treatment duration and a shift to additional treatment patterns with new drugs at the following lines. The time to inpatient death period suggested an improvement between the two periods. Thus, this study revealed that recent diversification of treatment options is preferred and contributes to improved outcomes in the clinical practice of multiple myeloma in Japan. Public Library of Science 2023-04-06 /pmc/articles/PMC10079007/ /pubmed/37023056 http://dx.doi.org/10.1371/journal.pone.0283931 Text en © 2023 Handa et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Handa, Hiroshi
Ishida, Tadao
Ozaki, Shuji
Mori, Asuka
Kato, Kenichi
Iida, Shinsuke
Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database
title Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database
title_full Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database
title_fullStr Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database
title_full_unstemmed Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database
title_short Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database
title_sort treatment pattern and clinical outcomes in multiple myeloma patients in japan using the medical data vision claims database
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079007/
https://www.ncbi.nlm.nih.gov/pubmed/37023056
http://dx.doi.org/10.1371/journal.pone.0283931
work_keys_str_mv AT handahiroshi treatmentpatternandclinicaloutcomesinmultiplemyelomapatientsinjapanusingthemedicaldatavisionclaimsdatabase
AT ishidatadao treatmentpatternandclinicaloutcomesinmultiplemyelomapatientsinjapanusingthemedicaldatavisionclaimsdatabase
AT ozakishuji treatmentpatternandclinicaloutcomesinmultiplemyelomapatientsinjapanusingthemedicaldatavisionclaimsdatabase
AT moriasuka treatmentpatternandclinicaloutcomesinmultiplemyelomapatientsinjapanusingthemedicaldatavisionclaimsdatabase
AT katokenichi treatmentpatternandclinicaloutcomesinmultiplemyelomapatientsinjapanusingthemedicaldatavisionclaimsdatabase
AT iidashinsuke treatmentpatternandclinicaloutcomesinmultiplemyelomapatientsinjapanusingthemedicaldatavisionclaimsdatabase